FYERS
Home
/
Stocks
/
Profit Loss
/
CORONA Remedies Profit & Loss

CORONA Remedies Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
₹422 Cr₹353 Cr₹342 Cr₹361 Cr₹347 Cr₹294 Cr₹298 Cr₹314 Cr
₹3 Cr₹4 Cr₹2 Cr₹2 Cr₹2 Cr₹1 Cr₹76 L₹2 Cr
₹426 Cr₹357 Cr₹345 Cr₹363 Cr₹349 Cr₹295 Cr₹298 Cr₹316 Cr
₹343 Cr₹301 Cr₹269 Cr₹292 Cr₹286 Cr₹250 Cr₹238 Cr₹256 Cr
₹96 Cr₹66 Cr₹85 Cr₹81 Cr₹72 Cr₹56 Cr₹70 Cr₹69 Cr
₹3 Cr₹1 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr
₹80 Cr₹54 Cr₹55 Cr₹70 Cr₹61 Cr₹43 Cr₹58 Cr₹57 Cr
₹60 Cr₹45 Cr₹41 Cr₹52 Cr₹46 Cr₹31 Cr₹45 Cr₹43 Cr

Share Price Live Stats

Open (₹)2,214.20
Volume (₹)1.41 L
High (₹)2,250.80
Upper Circuit2,640.90
Low (₹)2,181.50
Lower Circuit1,760.70
Prev Close2,200.80
52W High (₹)2,270.10
Price2,236.10
52W Low (₹)1,336.60

Share Market Cap & Key Ratios Overview

M.Cap (₹)13456.10 Cr
Div. Yield (%)0.45
PE Ratio67.61
Debt to Equity0.19
Price to Book12.74
Book Value122.12
EPS (TTM)32.54
Face Value10.00
ROE (%)27.36

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
AUROPHARMANSE
DRREDDYNSE
LUPINNSE
MANKINDNSE
CORONANSE
LTP
1W Low
1W High
Market cap (₹)
1840-45.9 (-2.43%)
1834
1907.80
4,47,236Cr
9322-253 (-2.64%)
9119.50
9615
2,49,673Cr
4965.5+5.5 (0.11%)
4823
5000
1,87,460Cr
1119.1-26.4 (-2.30%)
1104.60
1167.70
1,11,521Cr
1366-18 (-1.30%)
1347.70
1398.40
1,11,484Cr
1969+22.1 (1.14%)
1832.70
1981.80
1,04,604Cr
1679.8-12.2 (-0.72%)
1646
1704
96,031Cr
1165.5+14.5 (1.26%)
1130
1182
95,220Cr
2095-9.7 (-0.46%)
2058
2135.50
94,883Cr
2280-29 (-1.26%)
2222
2331.60
92,770Cr
2236.1+142.9 (6.83%)
2054.80
2250.80
13,456Cr

Key Highlights of CORONA Remedies Ltd’s P&L

In 2026-03-31, CORONA Remedies Ltd reported total revenue of ₹1413.83Cr, compared with ₹1202.35Cr in 2025-03-31, reflecting CORONA Remedies Ltd turnover.

Depreciation was ₹37.87Cr and finance costs were ₹6.97Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹240.42Cr in 2026-03-31 as compared to ₹198.53Cr in 2025-03-31.

Net Profit (PAT) was ₹185.12Cr in 2026-03-31 compared with ₹149.43Cr in 2025-03-31.

Earnings per share (EPS) were ₹30.27 in 2026-03-31, compared with ₹24.43 in 2025-03-31.